Trump unveils deal with Eli Lilly and Novo Nordisk to lower costs and expand coverage for obesity drugs
Coverage of popular obesity drugs like Wegovy and Zepbound will expand to Medicare patients starting next year, with some drugs potentially costing as little as $150.
President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
What did you think of this news? Leave a comment below and/or share it on your social media. This way, we can inform more people about the hottest things in technology, science, innovation, and gaming!
This news was originally published in:
Original source
